Samuel Broder

Title: The Innovations of Samuel Broder: Enhancing Oral Bioavailability in Pharmaceuticals

Introduction

Samuel Broder, an innovative inventor based in Weston, FL, has made significant contributions to the field of pharmaceuticals through his ten patents. His work predominantly focuses on improving the oral bioavailability of pharmaceutical agents, particularly those used in the treatment of cancer.

Latest Patents

Among his latest patents, one notable invention is a method for increasing the oral bioavailability of antitumor agents. This method involves the co-administration of a pharmacologically active target agent, which may exhibit poor oral bioavailability, alongside an enhancing agent. For example, paclitaxel and cyclosporin A are administered either simultaneously or at specific intervals to maximize therapeutic effects.

Another of his pioneering patents outlines a method for the oral administration of taxane antineoplastic agents, like paclitaxel, to achieve effective blood levels in patients suffering from taxane-responsive diseases. This method not only improves bioavailability but also aims to reduce hypersensitivity reactions associated with traditional administration methods.

Career Highlights

Samuel Broder's career is marked by his role at Baker Norton Pharmaceuticals, Inc., where he continues to drive innovation in the pharmaceutical sector. His research has opened new pathways for effectively delivering crucial cancer therapies, showcasing his commitment to enhancing patient care through scientific advancements.

Collaborations

Throughout his career, Broder has collaborated with notable colleagues, including Kenneth L Duchin and Sami Selim. Together, they have worked on refining methodologies and compositions that aim to revolutionize the way cancer treatments are administered, underlining the importance of teamwork in innovation.

Conclusion

Samuel Broder stands out as a prominent figure in pharmaceutical innovation, particularly in enhancing the oral bioavailability of anticancer agents. His ongoing efforts at Baker Norton Pharmaceuticals reflect a dedication to improving therapeutic outcomes for patients facing challenging health conditions. As his inventions continue to evolve, they hold the potential to significantly impact cancer treatment protocols in the future.